全部 标题 作者
关键词 摘要

PLOS ONE  2014 

ADAM-12 as a Diagnostic Marker for the Proliferation, Migration and Invasion in Patients with Small Cell Lung Cancer

DOI: 10.1371/journal.pone.0085936

Full-Text   Cite this paper   Add to My Lib

Abstract:

Small cell lung cancer (SCLC) is highly aggressive and is characterized by malignant metastasis. Approximately 90% of patients die due to extensive metastasis. The extracellular matrix (ECM) is a natural barrier that can prevent cellular invasion and metastasis. Therefore, degradation of the ECM must take place in order for extensive metastasis to occur. A disintegrin and metalloprotease (ADAM) is a multi-domain protease that plays an important role in tumorigenesis, as well as tumor development, invasion and metastasis. However, there have been few reports on the expression and role of ADAMs in SCLC. In the current study, the expression and role of ADAMs in SCLC proliferation, invasion and metastasis was investigated. A total of 150 SCLC tissue samples were examined by immunohistochemistry for ADAMs expression. ADAM-12 was found to be abundantly expressed in 72.67% samples and other ADAMs were found to be expressed in 10% to 40% of samples. ADAM-12 levels in serum and urine, from 70 SCLC patients and 40 normal controls, were also measured using ELISA. ADAM-12 expression was significantly higher in SCLC patients than in healthy controls and in patients with extensive disease compared to those with more limited disease. Silencing the expression of ADAM-12 in H1688 cells through the use of specific siRNA significantly reduced cellular proliferation, invasion and metastasis. Supplementing the expression of ADAM-12-L or -S in H345 cells, significantly enhanced cellular proliferation, invasion and metastasis. Animal models with metastatic SCLC also exhibited increased expression of ADAM-12 along with enhanced invasion and metastasis. In brief, ADAM-12 is an independent prognostic factor and diagnostic marker, and is involved in the proliferation, invasion and metastasis of SCLC.

References

[1]  Zhang Y, He J (2013) The development of targeted therapy in small cell lung cancer. J Thorac Dis 5: 538–548.
[2]  Buttery RC, Rintoul RC, Sethi T (2004) Small cell lung cancer: the importance of the extracellular matrix. Int J Biochem Cell Biol 36: 1154–1160.
[3]  Chang MH, Lee K, Lee KY, Kim YS, Kim YK, et al. (2012) Prognostic role of integrin beta1, E-cadherin, and rac1 expression in small cell lung cancer. APMIS 120: 28–38.
[4]  Michael M, Babic B, Khokha R, Tsao M, Ho J, et al. (1999) Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17: 1802–1808.
[5]  Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG (2012) Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 181: 1895–1899.
[6]  Arribas J, Bech-Serra JJ, Santiago-Josefat B (2006) ADAMs, cell migration and cancer. Cancer Metastasis Rev 25: 57–68.
[7]  Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, et al. (2004) ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 10: 8363–8370.
[8]  Schutz A, Hartig W, Wobus M, Grosche J, Wittekind C, et al. (2005) Expression of ADAM15 in lung carcinomas. Virchows Arch 446: 421–429.
[9]  Ohtsuka T, Shiomi T, Shimoda M, Kodama T, Amour A, et al. (2006) ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int J Cancer 118: 263–273.
[10]  Rocks N, Paulissen G, Quesada Calvo F, Polette M, Gueders M, et al. (2006) Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br J Cancer 94: 724–730.
[11]  O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, et al. (2003) Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 105: 754–761.
[12]  Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, et al. (2005) A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 65: 4754–4761.
[13]  Costa FF, Verbisck NV, Salim AC, Ierardi DF, Pires LC, et al. (2004) Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene 23: 1481–1488.
[14]  Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, et al. (2005) Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131: 41–48.
[15]  Lei Y, Liu H, Yang Y, Wang X, Ren N, et al. (2012) Interaction of LHBs with C53 promotes hepatocyte mitotic entry: A novel mechanism for HBV-induced hepatocellular carcinoma. Oncol Rep 27: 151–159.
[16]  Le Pabic H, Bonnier D, Wewer UM, Coutand A, Musso O, et al. (2003) ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 37: 1056–1066.
[17]  Ding X, Yang LY, Huang GW, Wang W, Lu WQ (2004) ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 10: 2735–2739.
[18]  Nakada M, Miyamori H, Kita D, Takahashi T, Yamashita J, et al. (2005) Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol 110: 239–246.
[19]  Liu YJ, Xu Y, Yu Q (2006) Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 25: 2452–2467.
[20]  Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, et al. (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98: 418–425.
[21]  Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA (2004) ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 279: 51323–51330.
[22]  Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA (2011) ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem 286: 20758–20768.
[23]  Hu Z, Gu Y, Han B, Zhang J, Li Z, et al. (2012) Knockdown of AGR2 induces cellular senescence in prostate cancer cells. Carcinogenesis 33: 1178–1186.
[24]  Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, et al. (2009) WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51–62.
[25]  Thodeti CK, Albrechtsen R, Grauslund M, Asmar M, Larsson C, et al. (2003) ADAM12/syndecan-4 signaling promotes beta 1 integrin-dependent cell spreading through protein kinase Calpha and RhoA. J Biol Chem 278: 9576–9584.
[26]  Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM (1999) Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am J Pathol 154: 1489–1501.
[27]  Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C (2005) The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 26: 17–24.
[28]  Kodama T, Ikeda E, Okada A, Ohtsuka T, Shimoda M, et al. (2004) ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am J Pathol 165: 1743–1753.
[29]  Mori S, Tanaka M, Nanba D, Nishiwaki E, Ishiguro H, et al. (2003) PACSIN3 binds ADAM12/meltrin alpha and up-regulates ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 278: 46029–46034.
[30]  Tanaka M, Nanba D, Mori S, Shiba F, Ishiguro H, et al. (2004) ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J Biol Chem 279: 41950–41959.
[31]  Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, et al. (2007) Proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem 282: 436–444.
[32]  Atfi A, Dumont E, Colland F, Bonnier D, L'Helgoualc'h A, et al. (2007) The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor. J Cell Biol 178: 201–208.
[33]  Huang J, Bridges LC, White JM (2005) Selective modulation of integrin-mediated cell migration by distinct ADAM family members. Mol Biol Cell 16: 4982–4991.
[34]  Frohlich C, Klitgaard M, Noer JB, Kotzsch A, Nehammer C, et al. (2013) ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochem J 452: 97–109.
[35]  Mino N, Miyahara R, Nakayama E, Takahashi T, Takahashi A, et al. (2009) A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. J Surg Oncol 100: 267–272.

Full-Text

comments powered by Disqus